文献速递胸部肿瘤

TP53、KEAP1和STK11突变在局限期NSCLC中的预后与预测作用

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.
PubMed 文献 · Eur J Cancer · 2026-02-17

该研究基于ETOP Lungscape项目,对350例手术切除的局限期NSCLC训练队列及161例验证队列进行NGS检测,分析TP53、KEAP1和STK11突变的预后及预测价值。结果显示KEAP1突变与更差结局相关,尤其在辅助化疗患者中;TP53破坏性突变和STK11突变可能对辅助化疗有预测作用,但TP53结果未在验证队列中证实。

要点

  • KEAP1突变与局限期NSCLC患者更短的无复发生存和总生存相关。
  • TP53破坏性突变在接受辅助化疗患者中与更好TTR相关,但未在验证队列证实。
  • STK11突变与更好结局相关,TP53或STK11状态在未化疗患者中不影响结局。

核心结论

  • KEAP1突变与局限期NSCLC更差结局相关,尤其在接受辅助化疗的患者中。
  • TP53破坏性突变和STK11突变可能对辅助化疗有预测作用,但需进一步研究。

研究设计与样本

  • 训练队列为350例手术切除的ETOP Lungscape局限期NSCLC患者,验证队列为161例额外患者,均行NGS检测。
  • TP53突变按预测影响分为破坏性(d)和非破坏性(nd),破坏性突变导致p53蛋白功能完全丧失。

主要发现

  • 训练队列350例中,KEAP1突变占11%,STK11突变占14%;TP53野生型占31%,TP53-d占35%,TP53-nd占34%。
  • 161例接受辅助化疗患者中,TP53-d突变与更好TTR相关;KEAP1突变患者TTR和OS显著更短;STK11突变与更好结局相关。
  • 186例未接受化疗患者中,KEAP1突变患者OS显著更差,TP53或STK11状态不影响结局。
  • 训练队列中基线匹配亚组(n=206)显示TP53突变与化疗的交互作用对所有终点均有统计学意义。
  • KEAP1相关发现但在TP53相关发现在第二个161例队列中得到验证。

临床怎么用

  • 对局限期NSCLC术后患者检测KEAP1突变有助于识别辅助化疗后预后更差的高危人群。
  • TP53破坏性突变和STK11突变对辅助化疗的预测价值尚需前瞻性验证,暂不用于临床决策。

局限性

  • TP53突变的预测作用未在验证队列中证实,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TP53, STK11 and KEAP1 mutations are frequent in localized-stage non-small cell lung cancer (NSCLC). However, their prognostic and predictive role has not been fully investigated, particularly in relation to adjuvant treatment. METHODS: Tumor samples from a training cohort of 350 surgically resected ETOP Lungscape NSCLC patients and a validation cohort of 161 additional patients were genotyped using Next Generation Sequencing (NGS). TP53 mutations were classified as "disruptive" (d) or "non-disruptive" (nd) according to their predicted impact. Disruptive mutations are those leading to complete loss of function of the p53 protein. RESULTS: Among the 350 patients of the training cohort, 11 % harbored mutations in KEAP1 and 14 % in STK11. Regarding TP53 status, 31 % were wild type, 35 % carried TP53-d and 34 % TP53-nd mutations. For the 161 patients receiving adjuvant chemotherapy, TP53-d mutations associated with better time to relapse (TTR). Significantly shorter TTR and overall survival (OS) were observed in KEAP1 mutant patients while STK11 mutations correlated with better outcomes. Among the 186 patients not receiving chemotherapy, significantly worse OS was observed in KEAP1 mutant patients, while TP53 or STK11 status did not affect outcome. In a baseline-matched sub-cohort (n = 206), selected within the training cohort, the interaction between TP53 mutations and chemotherapy was statistically significant for all endpoints. The findings for KEAP1 but not for TP53 were validated in a second cohort of 161 patients. CONCLUSIONS: TP53-d and STK11 mutations might have a predictive impact in localized-stage NSCLC, but further investigation is needed. KEAP1 mutations associate with worse outcomes, especially in patients receiving adjuvant chemotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Molina-Vila MA, Tsourti Z, Vervita K, et al. Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project. Eur J Cancer. 2026. PMID: 41723072. doi:10.1016/j.ejca.2026.116583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。